|
|
|
Insider
Information: |
Mueller Peter |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
311,837 |
|
Indirect Shares
|
25,571 |
|
|
Direct
Value |
$69,562,624 |
|
|
Indirect Value
|
$12,351,816 |
|
|
Total
Shares |
337,408 |
|
|
Total
Value |
$81,914,440 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Global R&D, CSO |
2014-06-16 |
143,517 |
2014-06-16 |
25,571 |
Premium* |
|
Bioxcel Therapeutics Inc |
BTAI |
Director |
2019-08-23 |
168,320 |
2018-12-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
141 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-02-16 |
4 |
AS |
$38.55 |
$61,680 |
D/D |
(1,600) |
125,505 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-02-16 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
127,105 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-03-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
127,105 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-03-15 |
4 |
AS |
$43.08 |
$68,928 |
D/D |
(1,600) |
125,505 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-04-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
127,105 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-04-15 |
4 |
AS |
$39.61 |
$63,376 |
D/D |
(1,600) |
125,505 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-05-07 |
4 |
AS |
$35.78 |
$225,571 |
D/D |
(6,271) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-05-17 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-05-17 |
4 |
AS |
$37.39 |
$59,824 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-06-15 |
4 |
AS |
$34.93 |
$55,888 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-06-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-07-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-07-15 |
4 |
AS |
$34.24 |
$54,784 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-08-16 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-08-16 |
4 |
AS |
$36.38 |
$58,208 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-09-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-09-15 |
4 |
AS |
$37.22 |
$59,552 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-10-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-10-15 |
4 |
AS |
$35.55 |
$57,035 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-11-15 |
4 |
AS |
$34.43 |
$55,088 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-11-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-02-03 |
4 |
A |
$0.01 |
$145 |
D/D |
14,501 |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-11 |
4 |
OE |
$10.41 |
$638,025 |
D/D |
40,000 |
173,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-11 |
4 |
AS |
$47.83 |
$1,921,020 |
D/D |
(40,000) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-15 |
4 |
AS |
$47.28 |
$118,716 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
141 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|